Zum Hauptinhalt springen

Targeting unmet
medical needs

Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Additionally, the Company is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infections and inner ear therapeutics.

Targeting unmet
medical needs

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (xPhore™ platform). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Additionally, the Company is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infections and inner ear therapeutics.

Targeting unmet
medical needs

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets. Additionally, the Company has legacy programs in allergy and viral infections, and inner ear disorders, which it intends to partner as it plans to focus exclusively on the exciting opportunities in RNA.

Targeting unmet
medical needs

Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Additionally, the Company is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infections and inner ear therapeutics.

Latest news

Our Science

RNA Programs

Legacy Programs


Our Science

RNA Programs

Legacy Programs